Jazz Pharmaceuticals
Tracked across 6 events · 40 articles · First seen Apr 23, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Jazz Pharmaceuticals entered into a collaboration with AbCellera to discover and develop T-cell engaging multispecific antibodies for GI cancers and other solid tumors, expanding its oncology focus and potentially adding new therapies to its pipeline.
Jun 17, 2026 · 10 articles
Business
Impact: Jazz Pharmaceuticals is mentioned as Iannone's current employer; not directly affected by this event.
Jul 13, 2026 · 6 articles
Business
Impact: Jazz Pharmaceuticals is a partner of Zymeworks with exclusive rights to develop and commercialize zanidatamab in certain territories. The conference participation does not directly affect Jazz Pharmaceuticals.
Aug 11, 2026 · 6 articles
Business
Impact: Jazz Pharmaceuticals is a partner with exclusive rights to develop and commercialize zanidatamab in certain territories; mentioned in the company description but not directly involved in this event.
Jul 16, 2026 · 6 articles
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Listed as an existing partnership partner of Iambic, with no new action in this event.
Sep 21, 2026 · 6 articles
Business
Impact: Laura Hamill currently serves on the board of Jazz Pharmaceuticals.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Jazz Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard